News Channels

09 Aug 2017 Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
08 Aug 2017 RXi Pharmaceuticals Advances Immuno-Oncology Pipeline by Selecting Two sd-rxRNA Compounds for Preclinical Development and Sourcing cGMP Manufacturing
08 Aug 2017 Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group
08 Aug 2017 Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab
08 Aug 2017 Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
08 Aug 2017 Mitobridge’s Novel Treatment Approach for Duchenne Muscular Dystrophy Advances into Clinical Development
08 Aug 2017 Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma
08 Aug 2017 Amylyx Pharmaceuticals Doses First Patient in Phase II Clinical Trial of AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
08 Aug 2017 Selvita and The Leukemia & Lymphoma Society Announce Partnership to Advance SEL120 Into Phase I for AML Patients
08 Aug 2017 Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Disease Due to Alport Syndrome
08 Aug 2017 PreveCeutical™ Medical Inc. Signs Letter of Intent with UniQuest Pty Limited for Research & Development Program Engineering Peptide Therapeutics for Non-Addictive Analgesics
08 Aug 2017 Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA
08 Aug 2017 FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
07 Aug 2017 Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
07 Aug 2017 Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
07 Aug 2017 AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
07 Aug 2017 AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)
07 Aug 2017 Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol
07 Aug 2017 HitGen and LEO Pharma Enter Research Collaboration
07 Aug 2017 Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing